[{"address1": "1111 Kane Concourse", "address2": "Suite 301", "city": "Bay Harbor Islands", "state": "FL", "zip": "33154", "country": "United States", "phone": "781 652 4500", "website": "https://www.avenuetx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.", "fullTimeEmployees": 3, "companyOfficers": [{"maxAge": 1, "name": "Dr. Alexandra  MacLean M.D.", "age": 56, "title": "CEO & Director", "yearBorn": 1967, "fiscalYear": 2023, "totalPay": 413200, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. David  Jin", "age": 33, "title": "Interim CFO, COO & Corporate Secretary", "yearBorn": 1990, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Lindsay Allan Rosenwald", "age": 68, "title": "Executive Director", "yearBorn": 1955, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Scott A. Reines M.D., Ph.D.", "age": 76, "title": "Interim Chief Medical Officer", "yearBorn": 1947, "fiscalYear": 2023, "totalPay": 69120, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 3.5, "open": 3.5502, "dayLow": 3.47, "dayHigh": 3.59, "regularMarketPreviousClose": 3.5, "regularMarketOpen": 3.5502, "regularMarketDayLow": 3.47, "regularMarketDayHigh": 3.59, "beta": -0.197, "trailingPE": 0.27466455, "forwardPE": -1.045045, "volume": 10131, "regularMarketVolume": 10131, "averageVolume": 65778, "averageVolume10days": 28860, "averageDailyVolume10Day": 28860, "marketCap": 3274631, "fiftyTwoWeekLow": 3.21, "fiftyTwoWeekHigh": 91.5, "fiftyDayAverage": 3.71916, "twoHundredDayAverage": 14.00254, "currency": "USD", "enterpriseValue": -857368, "floatShares": 871522, "sharesOutstanding": 940986, "sharesShort": 39249, "sharesShortPriorMonth": 49530, "sharesShortPreviousMonthDate": 1717113600, "dateShortInterest": 1719532800, "sharesPercentSharesOut": 0.0417, "heldPercentInsiders": 0.01903, "heldPercentInstitutions": 0.01987, "shortRatio": 1.65, "shortPercentOfFloat": 0.0417, "impliedSharesOutstanding": 940986, "bookValue": 4.805, "priceToBook": 0.7242456, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -7181000, "trailingEps": 12.67, "forwardEps": -3.33, "lastSplitFactor": "1:75", "lastSplitDate": 1714089600, "52WeekChange": -0.96, "SandP52WeekChange": 0.24156773, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "ATXI", "underlyingSymbol": "ATXI", "shortName": "Avenue Therapeutics, Inc.", "longName": "Avenue Therapeutics, Inc.", "firstTradeDateEpochUtc": 1498570200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "ab3c15b5-e280-3b5c-b842-8e87c6276492", "messageBoardId": "finmb_310815442", "gmtOffSetMilliseconds": -14400000, "currentPrice": 3.48, "targetHighPrice": 12.0, "targetLowPrice": 12.0, "targetMeanPrice": 12.0, "targetMedianPrice": 12.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 1, "totalCash": 3194000, "totalCashPerShare": 3.394, "quickRatio": 2.262, "currentRatio": 2.344, "returnOnAssets": -1.25659, "freeCashflow": -18397876, "operatingCashflow": -10998000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-07-14"}]